Side-by-side research comparison of the leading weight-loss peptides studied in US laboratories — mechanism, half-life, and documentation.
Weight-loss peptides studied in the Australia are dominated by GLP-1 and multi-incretin receptor agonists, supplemented by lipolytic fragments such as AOD-9604. The table below summarizes the major documented profiles.
| Compound | Mechanism | Half-life (research) | Reference dose range |
|---|---|---|---|
| Tirzepatide | GIP + GLP-1 agonist | ~5 days | 2.5–15 mg weekly |
| Semaglutide | GLP-1 agonist | ~7 days | 0.25–2.4 mg weekly |
| Retatrutide | GIP + GLP-1 + GCG agonist | ~6 days | Per published trial titration |
| AOD-9604 | Lipolytic hGH fragment | Short | Per published research literature |
Documentation common to all weight-loss research peptides
- HPLC purity ≥98%
- LC-MS confirmed identity
- Counterion content
- Endotoxin per analytical method
Research use only. 3 Diamond Labs supplies materials strictly for in vitro and laboratory research. Nothing in this article constitutes medical, therapeutic, or dosage advice for human or animal use.
